Mesoblast Corporate Update
December 14 2020 - 4:55PM
Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in
allogeneic cellular medicines for inflammatory diseases, will host
a webcast today to provide a corporate update.
The webcast will begin at 9.00am AEDT, Tuesday,
December 15; 5.00pm EST, Monday, December 14, 2020. It can be
accessed via
https://webcast.boardroom.media/mesoblast-limited/20201214/NaN5fd6e483de11ae0019f60917
The archived webcast will be available on the
Investor page of the Company’s website: www.mesoblast.com
About Mesoblast Mesoblast is a
world leader in developing allogeneic (off-the-shelf) cellular
medicines. The Company has leveraged its proprietary mesenchymal
lineage cell therapy technology platform to establish a broad
portfolio of commercial products and late-stage product candidates.
Mesoblast has a strong and extensive global intellectual property
portfolio with protection extending through to at least 2040 in all
major markets. The Company’s proprietary manufacturing processes
yield industrial-scale, cryopreserved, off-the-shelf, cellular
medicines. These cell therapies, with defined pharmaceutical
release criteria, are planned to be readily available to patients
worldwide.
Remestemcel-L is being developed for inflammatory
diseases in children and adults including steroid refractory acute
graft versus host disease and moderate to severe acute respiratory
distress syndrome. Mesoblast has completed Phase 3 trials of
rexelemestrocel-L for advanced heart failure and chronic low back
pain. Two products have been commercialized in Japan and Europe by
Mesoblast’s licensees, and the Company has established commercial
partnerships in Europe and China for certain Phase 3 assets.
Mesoblast has locations in Australia, the United
States and Singapore and is listed on the Australian Securities
Exchange (MSB) and on the Nasdaq (MESO). For more information,
please see www.mesoblast.com, LinkedIn: Mesoblast Limited and
Twitter: @Mesoblast
Forward-Looking Statements This
announcement includes forward-looking statements that relate to
future events or our future financial performance and involve known
and unknown risks, uncertainties and other factors that may cause
our actual results, levels of activity, performance or achievements
to differ materially from any future results, levels of activity,
performance or achievements expressed or implied by these
forward-looking statements. All statements other than statements of
historical fact are forward-looking statements, which are often
indicated by terms such as “anticipate,” “believe,” “could,”
“estimate,” “expect,” “goal,” “intend,” “likely,” “look forward
to,” “may,” “plan,” “potential,” “predict,” “project,” “should,”
“will,” “would” and similar expressions and variations thereof. We
make such forward-looking statements pursuant to the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995
and other federal securities laws. Forward-looking statements
should not be read as a guarantee of future performance or results,
and actual results may differ from the results anticipated in these
forward-looking statements, and the differences may be material and
adverse. The risks, uncertainties and other factors that may impact
our forward-looking statements include, but are not limited to: the
timing, progress and results of Mesoblast’s preclinical and
clinical studies; Mesoblast’s ability to advance product candidates
into, enroll and successfully complete, clinical studies; the
timing or likelihood of regulatory filings and approvals; and the
pricing and reimbursement of Mesoblast’s product candidates, if
approved; Mesoblast’s ability to establish and maintain
intellectual property on its product candidates and Mesoblast’s
ability to successfully defend these in cases of alleged
infringement. You should read this press release together with our
risk factors, in our most recently filed reports with the SEC or on
our website. Uncertainties and risks that may cause Mesoblast’s
actual results, performance or achievements to be materially
different from those which may be expressed or implied by such
statements, and accordingly, you should not place undue reliance on
these forward-looking statements. Unless required by law, we do not
undertake any obligations to publicly update or revise any
forward-looking statements, whether as a result of new information,
future developments or otherwise.
Release authorized by the Chief Executive
For more information, please contact:
Corporate Communications / Investors |
|
|
Schond Greenway T: +1 212 880 2060
E: schond.greenway@mesoblast.com |
|
Paul Hughes T: +61 3 9639 6036 E: paul.hughes@mesoblast.com |
|
|
|
Media Kristen Bothwell T: +1 917 613 5434
E: kbothwell@rubenstein.com |
|
|
|
|
|
Mesoblast (NASDAQ:MESO)
Historical Stock Chart
From Jun 2024 to Jul 2024
Mesoblast (NASDAQ:MESO)
Historical Stock Chart
From Jul 2023 to Jul 2024